Literature DB >> 12560069

Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells.

Abhijit Mazumdar1, Rakesh Kumar.   

Abstract

Stimulation of p21-activated kinase-1 (Pak1) and estradiol-estrogen receptor-alpha in mammary cancer cells promotes cell survival. We sought to determine whether estrogen stimulates the Pak1 pathway. We found that estrogen rapidly activated Pak1 kinase activity in a phosphatidylinositol 3-kinase-insensitive manner. Furthermore, estrogen induced phosphorylation and perinuclear localization of the cell survival forkhead transcription factor FKHR in the cytoplasm in a Pak1-dependent manner. In addition, Pak1 directly interacted with FKHR and phosphorylated it. The noticed phosphorylation-dependent exclusion of FKHR from the nucleus impaired the ability of FKHR to activate its target Fas ligand promoter containing the FKHR binding motif (FRE) in cells treated with estrogen or expressing catalytically active Pak1. In contrast, expression of the dominant-negative auto-inhibitory domain of Pak1 (Pak amino acids 83-149) promoted the ability of FKHR to activate transcription from FRE. Together, these results identify a novel signaling pathway linking estrogen action to Pak1 signaling, and Pak1 to FKHR, suggesting that Pak1 is an important mediator of estrogen's cell survival functions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12560069     DOI: 10.1016/s0014-5793(02)03846-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  40 in total

Review 1.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

2.  The p21-activated kinase (PAK1) is involved in diet-induced beta cell mass expansion and survival in mice and human islets.

Authors:  Miwon Ahn; Stephanie M Yoder; Zhanxiang Wang; Eunjin Oh; Latha Ramalingam; Ragadeepthi Tunduguru; Debbie C Thurmond
Journal:  Diabetologia       Date:  2016-07-09       Impact factor: 10.122

Review 3.  Integration of the extranuclear and nuclear actions of estrogen.

Authors:  Ellis R Levin
Journal:  Mol Endocrinol       Date:  2005-02-10

4.  Functional regulation of oestrogen receptor pathway by the dynein light chain 1.

Authors:  Suresh K Rayala; Petra den Hollander; Seetharaman Balasenthil; Zhibo Yang; Russell R Broaddus; Rakesh Kumar
Journal:  EMBO Rep       Date:  2005-06       Impact factor: 8.807

Review 5.  P21 activated kinases: structure, regulation, and functions.

Authors:  Chetan K Rane; Audrey Minden
Journal:  Small GTPases       Date:  2014-03-21

Review 6.  p21-Activated Kinases in Thyroid Cancer.

Authors:  Luis Bautista; Christina M Knippler; Matthew D Ringel
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

7.  Endothelin-1 couples betaPix to p66Shc: role of betaPix in cell proliferation through FOXO3a phosphorylation and p27kip1 down-regulation independently of Akt.

Authors:  Ahmed Chahdi; Andrey Sorokin
Journal:  Mol Biol Cell       Date:  2008-04-02       Impact factor: 4.138

8.  Differential gene regulation of GHSR signaling pathway in the arcuate nucleus and NPY neurons by fasting, diet-induced obesity, and 17β-estradiol.

Authors:  Ali Yasrebi; Anna Hsieh; Kyle J Mamounis; Elizabeth A Krumm; Jennifer A Yang; Jason Magby; Pu Hu; Troy A Roepke
Journal:  Mol Cell Endocrinol       Date:  2015-11-11       Impact factor: 4.102

9.  Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells.

Authors:  Catia Morelli; Marilena Lanzino; Cecilia Garofalo; Pamela Maris; Elvira Brunelli; Ivan Casaburi; Stefania Catalano; Rosalinda Bruno; Diego Sisci; Sebastiano Andò
Journal:  Mol Cell Biol       Date:  2009-11-23       Impact factor: 4.272

Review 10.  PAK signaling in oncogenesis.

Authors:  P R Molli; D Q Li; B W Murray; S K Rayala; R Kumar
Journal:  Oncogene       Date:  2009-05-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.